Information Provided By:
Fly News Breaks for July 28, 2016
BMRN
Jul 28, 2016 | 05:55 EDT
Piper Jaffray analyst Joshua Schimmer says BioMarin's updated data from its ongoing Phase 1/2 hemophilia A gene therapy study were "impressive," but also raised new questions. While the potential for gene therapy to have robust efficacy that may functionally "cure" hemophilia A patients is exciting, there are several questions around the therapeutic index, ALT elevation, and the optimized dose which will need to be addressed over time and with additional studies, Schimmer writes in a research note to investors. He has an Overweight rating on BioMarin with a $107 price target.
News For BMRN From the Last 2 Days
There are no results for your query BMRN